Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
APRE Stock Forecast 2026-2027
$0.70
Current Price
$8.64M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to APRE Price Targets
+759.8%
To High Target of $6.00
+616.5%
To Median Target of $5.00
+72.0%
To Low Target of $1.20
APRE Price Momentum
-4.1%
1 Week Change
-4.1%
1 Month Change
-57.8%
1 Year Change
-17.6%
Year-to-Date Change
-68.6%
From 52W High of $2.22
+27.3%
From 52W Low of $0.55
📊 TOP ANALYST CALLS
Did APRE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aprea Therapeutics is one of their latest high-conviction picks.
Latest APRE Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, APRE has a bullish consensus with a median price target of $5.00 (ranging from $1.20 to $6.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $0.70, the median forecast implies a 616.5% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Driscoll at Wedbush, projecting a 759.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APRE Analyst Ratings
4
Buy
0
Hold
0
Sell
APRE Price Target Range
Low
$1.20
Average
$5.00
High
$6.00
Current: $0.70
Latest APRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APRE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2026 | Wedbush | Robert Driscoll | Outperform | Maintains | $6.00 |
| May 7, 2026 | Oppenheimer | Matthew Biegler | Outperform | Initiates | $5.00 |
| Mar 31, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Mar 31, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 10, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Jan 29, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jan 15, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 17, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 18, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 24, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 13, 2024 | Wedbush | Outperform | Reiterates | $N/A | |
| Aug 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 24, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 17, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 27, 2024 | Wedbush | Outperform | Maintains | $N/A | |
| Mar 26, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 1, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 13, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Clear Creek Independent School District (APRE) Competitors
The following stocks are similar to Aprea Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Clear Creek Independent School District (APRE) Financial Data
Clear Creek Independent School District has a market capitalization of $8.64M with a P/E ratio of 0.5x. The company generates $123,296 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -10,202.0% and return on equity of -40.4%.
Valuation Metrics
Market Cap
$8.64M
Enterprise Value
$-36,798,476
P/E Ratio
0.5x
PEG Ratio
0.0x
Price/Sales
73.5x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-10,202.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+537.7%
Current Ratio
8.9x
Debt/Equity
0.0x
ROE
-40.4%
ROA
-23.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Clear Creek Independent School District (APRE) Business Model
About Clear Creek Independent School District
What They Do
Public school district serving pre-K to 12th grade.
Business Model
The district generates revenue primarily through state funding, local property taxes, and grants. It allocates its budget to provide quality education and services for approximately 38,000 students, while maintaining transparency in financial reporting and operations.
Additional Information
Clear Creek Independent School District is recognized for its commitment to academic excellence and offers specialized programs in partnership with local businesses and higher education institutions. It covers a 100 square mile area across 13 municipalities in Texas and emphasizes a supportive environment for students' unique talents.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
8
CEO
Dr. Oren Gilad Ph.D.
Country
United States
IPO Year
2019
Website
aprea.comClear Creek Independent School District (APRE) Latest News & Analysis
Latest News
Quick Summary
Aprea Therapeutics reported early clinical activity for its WEE1 inhibitor APR-1051, showing partial responses in various tumors. Patient expansion in specific cancers is ongoing, with completion expected by Q2 2027.
Why It Matters
Positive clinical results for Aprea's APR-1051, showing early efficacy and manageable side effects, could boost investor confidence and indicate potential for future market success.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), indicating improved earnings prospects and potential for stock price increase.
Why It Matters
Aprea Therapeutics’ upgrade to Zacks Rank #2 signals positive earnings outlook, potentially boosting investor confidence and driving stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2 months ago
Quick Summary
Aprea Therapeutics (Nasdaq: APRE) announced its Q1 2026 financial results and a business update, focusing on targeted therapies for biomarker-defined cancers.
Why It Matters
Aprea Therapeutics' financial results and business update signal its progress in oncology, potentially affecting stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aprea Therapeutics (Nasdaq: APRE) announced its abstract on the phase 1 study of WEE1 inhibitor APR-1051 has been accepted for presentation at the ASCO Annual Meeting, May 29 - June 2, 2026.
Why It Matters
Aprea Therapeutics' acceptance of a significant clinical study abstract at ASCO signals potential advancements in cancer treatments, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aprea Therapeutics reported a confirmed partial response for APR-1051, a WEE1 inhibitor, in biomarker-defined cancers. Further trial updates are expected in Q2 2026.
Why It Matters
Aprea's promising clinical data for APR-1051 could lead to increased investor confidence and stock price appreciation, indicating strong potential in the oncology market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aprea Therapeutics has secured an oversubscribed private placement financing, expected to yield approximately $30 million, led by Soleus Capital and other investors.
Why It Matters
Aprea Therapeutics secured $30 million in an oversubscribed financing, indicating strong investor confidence and enhancing its capacity for developing targeted cancer therapies, potentially boosting future valuations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About APRE Stock
What is Clear Creek Independent School District's (APRE) stock forecast for 2027?
Based on our analysis of 7 Wall Street analysts, Clear Creek Independent School District (APRE) has a median price target of $5.00. The highest price target is $6.00 and the lowest is $1.20.
Is APRE stock a good investment in 2027?
According to current analyst ratings, APRE has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APRE stock?
Wall Street analysts predict APRE stock could reach $5.00 in the next 12 months. This represents a 616.5% increase from the current price of $0.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Clear Creek Independent School District's business model?
The district generates revenue primarily through state funding, local property taxes, and grants. It allocates its budget to provide quality education and services for approximately 38,000 students, while maintaining transparency in financial reporting and operations.
What is the highest forecasted price for APRE Clear Creek Independent School District?
The highest price target for APRE is $6.00 from Robert Driscoll at Wedbush, which represents a 759.8% increase from the current price of $0.70.
What is the lowest forecasted price for APRE Clear Creek Independent School District?
The lowest price target for APRE is $1.20 from at , which represents a 72.0% increase from the current price of $0.70.
What is the overall APRE consensus from analysts for Clear Creek Independent School District?
The overall analyst consensus for APRE is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are APRE stock price projections?
Stock price projections, including those for Clear Creek Independent School District, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:07 AM UTC